Rashtriya Newsflash

DelveInsight’s “ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the ANCA Vasculitis, historical and forecasted epidemiology as well as the ANCA Vasculitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the ANCA Vasculitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ANCA Vasculitis Market Forecast

Some of the key facts of the ANCA Vasculitis Market Report:

• The ANCA Vasculitis market size is expected to expand from approximately USD 1.8 billion in 2025 to nearly USD 3.8 billion by 2036, growing at a CAGR of about 6.5% throughout the forecast period from 2026 to 2036.

• In March 2026, Amgen announced continued commercial expansion of avacopan (TAVNEOS) for ANCA-associated vasculitis following increasing global uptake as a steroid-sparing complement 5a receptor inhibitor. The company continues to generate real-world evidence supporting its role in reducing glucocorticoid-related toxicity in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

• In December 2025, Roche/Genentech highlighted ongoing long-term follow-up data for rituximab (RITUXAN/MabThera) in ANCA-associated vasculitis, reinforcing its continued use as a key therapy for remission induction and maintenance in GPA and MPA patients.

• In October 2025, Chemocentryx (Amgen) presented additional real-world and long-term outcomes data for avacopan (TAVNEOS), demonstrating sustained remission benefits and reduced steroid exposure in patients with severe ANCA-associated vasculitis.

• In June 2025, InflaRx announced continued development progress for vilobelimab (IFX-1), a monoclonal antibody targeting complement C5a, with ongoing interest in complement pathway inhibition as a potential future treatment strategy for ANCA-associated vasculitis.

• Induction typically involves cyclophosphamide or rituximab with high-dose steroids, while maintenance uses methotrexate or azathioprine; newer approved options include TAVNEOS (avacopan) and NUCALA (mepolizumab).

• According to DelveInsight’s estimates, there were approximately 226,000 diagnosed prevalent cases of ANCA vasculitis across the 7MM in 2025, with the United States accounting for the highest share.

• Among EU4, Germany accounted for the largest number of diagnosed prevalent cases of ANCA Vasculitis, followed by Italy, whereas Spain accounted for the lowest cases in 2025.

• In 2025, pANCAs/MPO-ANCAs represented the most commonly diagnosed antibody-specific subtype of AAV in MPA, accounting for approximately 28,000 cases in the US.

• In 2025, the diagnosed prevalent cases of MPA by organ involvement in the UK were highest in renal impairment, followed by other organs such as the lower respiratory tract, cutaneous manifestations, gastrointestinal involvement, nervous system, upper respiratory tract, cardiovascular involvement, and eye involvement.

• Granulomatosis with polyangiitis was found to be more prevalent than any other type of ANCA Vasculitis in the United States (~35,000).

• Key ANCA Vasculitis Companies: CSL, Amgen, NS Pharma, Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

• Key ANCA Vasculitis Therapies: Mepolizumab (NUCALA), Avacopan (TAVNEOS), Depemokimab (GSK3511294), NS-229, TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

• The ANCA Vasculitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ANCA Vasculitis pipeline products will significantly revolutionize the ANCA Vasculitis market dynamics.

ANCA Vasculitis Overview

ANCA Vasculitis (AAV) is a group of autoimmune diseases that cause inflammation of blood vessels, leading to damage in various organs, including the kidneys, lungs, and upper respiratory tract. The condition is characterized by the presence of antineutrophil cytoplasmic antibodies (ANCA) in the blood, which target and attack certain white blood cells, causing vessel inflammation. AAV includes conditions like granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Symptoms often include fatigue, fever, weight loss, and organ-specific signs depending on the affected area. Treatment usually involves immunosuppressive drugs to reduce inflammation and manage symptoms

Get a Free sample for the ANCA Vasculitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anca-vasculitis-market

ANCA Vasculitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

ANCA Vasculitis Epidemiology Segmentation:

The ANCA Vasculitis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of ANCA Vasculitis

• Type-specific Diagnosed Prevalent Cases of ANCA Vasculitis

• Severity-specific Diagnosed Prevalence of ANCA Vasculitis

• Diagnosed Prevalent Cases of ANCA Vasculitis by Organ Involvement

• Diagnosed Prevalent Cases of ANCA Vasculitis by Antibody Type

Download the report to understand which factors are driving ANCA Vasculitis epidemiology trends @ ANCA Vasculitis Epidemiology Forecast

ANCA Vasculitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ANCA Vasculitis market or expected to get launched during the study period. The analysis covers ANCA Vasculitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the ANCA Vasculitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

ANCA Vasculitis Therapies and Key Companies

• Mepolizumab (NUCALA): GlaxoSmithKline

• Avacopan (TAVNEOS): CSL/Amgen

• Depemokimab (GSK3511294): GlaxoSmithKline

• NS-229: NS Pharma

• TAVNEOS (avacopan): Chemocentryx/Amgen

• Depemokimab (GSK3511294): GlaxoSmithKline

• FASENRA (benralizumab): AstraZeneca

• BDB-001 injection: Staidson (Beijing) Biopharmaceuticals

• Avacopan: Amgen

• Iptacopan: Novartis

• NM8074: NovelMed Therapeutics

• Sparsentan: University of Edinburgh

• povetacicept: Alpine Immune Sciences, Inc.

• Rituximab: Alentis Therapeutics AG

Discover more about therapies set to grab major ANCA Vasculitis market share @ ANCA Vasculitis Treatment Landscape

ANCA Vasculitis Market Drivers

• Increasing Prevalence and Diagnosis of Autoimmune Diseases: Improved awareness and advancements in diagnostic testing are leading to earlier detection of ANCA-associated vasculitis (AAV), supporting treatment demand.

• Growing Adoption of Targeted Therapies: The introduction of biologics, B-cell-targeted therapies, and complement pathway inhibitors is improving disease management and expanding treatment options.

• Rising Research and Clinical Trial Activity: Ongoing investments in autoimmune disease research are accelerating the development of innovative therapies for ANCA vasculitis.

• Advancements in Diagnostic Technologies: Improved ANCA testing, biomarker identification, and disease-monitoring tools are enabling more accurate diagnosis and personalized treatment approaches.

ANCA Vasculitis Market Barriers

• Rare Disease Population: The relatively low prevalence of ANCA vasculitis limits the overall patient pool and market size.

• High Cost of Advanced Therapies: Biologics and targeted immunotherapies can be expensive, creating affordability and access challenges in certain regions.

• Risk of Treatment-Related Adverse Events: Long-term immunosuppression may increase the risk of infections, malignancies, and other complications.

• Diagnostic Delays and Disease Complexity: Nonspecific symptoms and disease heterogeneity can result in delayed diagnosis and treatment initiation.

Scope of the ANCA Vasculitis Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key ANCA Vasculitis Companies: GlaxoSmithKline, CSL, Amgen, NS Pharma, Chemocentryx, Amgen, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

• Key ANCA Vasculitis Therapies: Mepolizumab (NUCALA), Avacopan (TAVNEOS), Depemokimab (GSK3511294), NS-229, TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

• ANCA Vasculitis Therapeutic Assessment: ANCA Vasculitis current marketed and ANCA Vasculitis emerging therapies

• ANCA Vasculitis Market Dynamics: ANCA Vasculitis market drivers and ANCA Vasculitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• ANCA Vasculitis Unmet Needs, KOL’s views, Analyst’s views, ANCA Vasculitis Market Access and Reimbursement

To know more about ANCA Vasculitis companies working in the treatment market, visit @ ANCA Vasculitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. ANCA Vasculitis Market Report Introduction

2. Executive Summary for ANCA Vasculitis

3. SWOT analysis of ANCA Vasculitis

4. ANCA Vasculitis Patient Share (%) Overview at a Glance

5. ANCA Vasculitis Market Overview at a Glance

6. ANCA Vasculitis Disease Background and Overview

7. ANCA Vasculitis Epidemiology and Patient Population

8. Country-Specific Patient Population of ANCA Vasculitis

9. ANCA Vasculitis Current Treatment and Medical Practices

10. ANCA Vasculitis Unmet Needs

11. ANCA Vasculitis Emerging Therapies

12. ANCA Vasculitis Market Outlook

13. Country-Wise ANCA Vasculitis Market Analysis (2022–2036)

14. ANCA Vasculitis Market Access and Reimbursement of Therapies

15. ANCA Vasculitis Market Drivers

16. ANCA Vasculitis Market Barriers

17. ANCA Vasculitis Appendix

18. ANCA Vasculitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/